<DOC>
	<DOCNO>NCT00873431</DOCNO>
	<brief_summary>The main aim clinical study investigate safety tolerability different dose strength IC47 6 month first vaccination . A total 32 healthy subject ( male female ) participate clinical study . The subject divide 4 group 8 subject . Thirty ( 30 ) μg 150 μg IC47 administer three time intervals 42 day .</brief_summary>
	<brief_title>Open-Label Study Assessing The Safety , Immunogenicity Dose Response IC47</brief_title>
	<detailed_description>This Phase 1 study conduct four group 8 healthy subject single study center . 32 subject enrol . The follow table show design different study group . The amount protein show table refers total protein content comprise equal amount three individual component .</detailed_description>
	<mesh_term>Pneumococcal Infections</mesh_term>
	<criteria>Written inform consent Healthy adult ≥ 18 &lt; /= 65 female subject : post‐menopausal practice reliable method contraception study History autoimmune diseases malignancy . History severe hypersensitivity reaction anaphylaxis . Immunodeficiency due immunosuppressive therapy . Infection HIV , Hepatitis B Hepatitis C. Pregnancy , lactation Vulnerable subject</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Prevention pneumococcal infection</keyword>
</DOC>